LHLabcorp
The financials
Labcorp by the numbers
Labcorp (LH) reported revenue of $3.81B in Q3 2026 (quarter ended Sep 30, 2026), up 6.9% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $263M (6.9% of revenue). For the full year FY2025, revenue was $14.0B (+7.2% year on year) and net income $877M. Its largest segment in Q2 2026 (quarter ended Jun 30, 2026) was Diagnostics at $2.90B, 78% of the disclosed total, well ahead of Biopharma Laboratory Services at 22%. The next results filing is expected around Feb 16, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $3.81B | $3.56B | +6.9% |
| Gross profit | $1.11B | $1.03B | +8.1% |
| Operating income | $402M | $397M | +1.4% |
| Net income | $263M | $261M | +0.7% |
| Diluted EPS | $3.22 | $3.12 | +3.2% |
| Operating | Revenue | Share |
|---|---|---|
| Diagnostics | $2.90B | 78% |
| Biopharma Laboratory Services | $836M | 22% |
Over its last three fiscal years Labcorp booked income tax of 23.6% of its pretax profit, above the 21.3% median for US companies in our tax study.
Business segments
Revenue split by operating segment, from SEC XBRL filings.
- Diagnostics$2.90B$2.90Bvs last quarter +5.0%vs a year ago +5.5%+5.0%+5.5%
- Biopharma Laboratory Services$836.2M$836.2Mvs last quarter +7.1%vs a year ago +6.5%+7.1%+6.5%
Diagnostics & Research
The closest names by size in the same industry